**The Royal College of Physicians and Surgeons of Canada requires that all presenters and members of Planning Committees complete this Disclosure of Conflict of Interest form.**

The 2007 CMA Guidelines for Physicians in Interaction with Industry, Section 24, states that, *“CME/CPD organizers and individual physician presenters are responsible for ensuring the scientific validity, objectivity and completeness of CME/CPD activities. Organizers and individual presenters must disclose to the participants at their CME/CPD events any financial affiliations with manufacturers of products mentioned at the event or with manufacturers of competing products.”1*

This serves as the basis for the Royal College’s Conflict of Interest policies; however, the Royal College goes beyond this definition and applies this policy in a broader context. The intent of this policy is not to prohibit speakers from presenting, but rather to inform the audience of any bias that speakers may have.

**Definition:**

A Conflict of Interest may occur in situations where the personal and professional interests of individuals may have actual, potential or apparent influence over their judgment and actions.

1. All financial or ‘in kind’ relationships (not only those relevant to the subject being discussed) encompassing the previous two (2) years must be disclosed.
2. It is the presenter’s responsibility to ensure that their presentation (and any recommendations) is balanced and reflects the current scientific literature. Unapproved use of products or services must be declared within the presentation. The only caveat to this guideline is where there is only one treatment or management strategy.
3. Disclosure must be done verbally, displayed in writing on a slide at the beginning of a presentation or included in the written conference materials.
4. The attached form must be completed and submitted to the planning committee prior to the start date of the event or program.
* Part 1 must be completed by all Speakers and Planning Committee members.
* Part 2 must be completed by all Speakers.
1. Examples of relationships that must be disclosed include but are not limited to the following:
* Any direct financial interest in a commercial entity such as a pharmaceutical organization, medical devices company or communications firm (“ the Organization”)
* Investments held in the Organization
* Membership on the Organization’s Advisory Board or similar committee
* Current or recent participation in a clinical trial sponsored by the Organization
* Member of a Speakers Bureau
* Holding a patent for a product referred to in the CME/CPD activity or that is marketed by a commercial organization
1. Failure to disclose or false disclosure may require the Planning Committee to replace the speaker.

Reference:1 CMA Policy: Guidelines for Physicians in Interactions with Industry. Approved 2007-Dec-01. <http://policybase.cma.ca/dbtw-wpd/Policypdf/PD08-01.pdf>**Part 1 All Speakers and Planning Committee members must complete this form and submit to the planning committee. Disclosure must be made to the audience whether you do or do not have a relationship with a commercial entity such as a pharmaceutical organization, medical device company or a communications firm.**

[ ]  I do **not** have an affiliation (financial or otherwise) with a pharmaceutical, medical device or communications organization. Speakers who have no involvement with industry should inform the audience that they cannot identify any conflict of interest.

[ ]  I **have/had** an affiliation (financial or otherwise) with a pharmaceutical, medical device or communications organization. Complete the section below as it applies to you during the past two calendar years. Please indicate the commercial organization(s) with which you have/had affiliations, and briefly explain what connection you have/had with the organization. You must disclose this information to your audience.

|  |  |  |  |
| --- | --- | --- | --- |
|  |   | **Company/Organization** | **Details** |
| **A** | I am a member of an Advisory Board or equivalent with a commercial organization. |  |  |
| **B** | I am a member of a Speakers bureau. |  |  |
| **C** | I have received payment from a commercial organization. (including gifts or other consideration or ‘in kind’ compensation) |  |  |
| **D** | I have received a grant(s) or an honorarium from a commercial organization. |  |  |
| **E** | I hold a patent for a product referred to in the CME/CPD program or that is marketed by a commercial organization. |  |  |
| **F** | I hold investments in a pharmaceutical organization, medical devices company or communications firm. |  |  |
| **G** | I am currently participating in or have participated in a clinical trial within the past two years. |  |  |

**Part 2 Speakers only:**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  |  | **Yes** | **No** | You must declare all off-label use to the audience during your presentation. |
| **H** | I intend to make therapeutic recommendations for medications that have not received regulatory approval (i.e. “off-label” use of medication). |  |  |
| **I** | The Royal College requires faculty presentations to be consistent in their use of either generic names or both generic and trade names during their presentation.  |

**Check one:** **[ ]  Faculty/Speaker** **[ ]  Planning Committee Member**

**Activity Title: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ Date of the Activity: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

**Acknowledgment: *I, \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_, acknowledge that the above information is accurate and I understand that this information will be publicly available.***

**Signature: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ Date**: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**Once completed, this form must be submitted to the Chair of the planning committee.**